GLGC Gene Logic Inc. (MM)

Gene Logic Inc. (NASDAQ:GLGC) announced today it has completed expansion and upgrade of its contract study services facilities, increasing its general toxicology testing capacity by 55 percent to meet growing demand from pharmaceutical and biotechnology clients for nonclinical testing. Gene Logic Laboratories Inc., the Company's contract study services business unit, now has approximately 100,000 square feet of facilities dedicated to nonclinical testing services. Additionally, Gene Logic added skilled staff and enhanced training programs for new and existing staff. V.W. Brinkerhoff III, senior vice president and general manager, Gene Logic Laboratories, commented, "Drug candidate toxicology testing is essential to the drug development and approval process, and the demand for testing has grown faster than the industry's ability to provide it. With this expansion of facilities and staff, we have positioned Gene Logic as a prime partner for our current and potential client base. The added space and specialized facilities enable Gene Logic to better address increasing client requirements with accuracy and speed." Gene Logic Overview Gene Logic aspires to be the most valued drug development solutions partner for the pharmaceutical industry. Gene Logic applies its broad and unique mix of technologies, talent and methodologies to work on behalf of its partners to enable pharmaceutical and biotechnology companies to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.